Physician profile
Samuel Cho
NPI 1801839501
$6,163.60
in general payments reported to CMS, 2019-2025
23 companies · $673 in 2025
The $673 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,159 · 2020: $398 · 2021: $499 · 2022: $637 · 2023: $389 · 2024: $410 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141 · Travel and Lodging: $312 · Education: $18.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.95 |
| Travel and Lodging | $311.58 |
| Education | $18.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,314.35 | 2019 | |
| Braintree Laboratories, INC. | $1,109.57 | 2019-2021 | |
| Abbvie INC. | $670.70 | 2019-2025 | Linzess, Viberzi |
| Cerapedics INC. | $630.78 | 2022-2025 | I-Factor Peptide Enhanced Bone Graft |
| Gilead Sciences, INC. | $259.83 | 2019-2025 | |
| Amarin Pharma, INC. | $242.73 | 2019-2020 | |
| Vivus LLC | $203.68 | 2024-2025 | Pancreaze |
| Nuvasive, INC. | $192.04 | 2020 | |
| Redhill Biopharma INC. | $174.82 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $160.02 | 2022-2025 | Ocaliva |
| Stryker Corporation | $156.52 | 2023 | Everest Spinal System |
| Thd America, INC. | $153.86 | 2024 | |
| Nestle Healthcare Nutrition INC. | $147.29 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.88 | 2023 | Xifaxan |
| Amgen INC. | $125.00 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $115.76 | 2019 | |
| Phathom Pharmaceuticals, INC. | $103.70 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $81.95 | 2019 | |
| Insmed, INC. | $81.68 | 2019 | |
| Celltrion USA INC. | $43.69 | 2024-2025 | Vegzelma, Zymfentra |
| Aimmune Therapeutics, INC. | $19.06 | 2024 | |
| Ferring Pharmaceuticals INC. | $17.02 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.67 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.